Furthermore, targeting of endogenous NO production by iNOS silencing in ER+ breast cancer cells displayed inhibition of mammosphere formation and expression of CSC-associated markers, while it significantly reversed tumor resistance to tamoxifen treatment [280]. The gene discussed is NOS2; the disease is breast carcinoma.